KALTF - Claritas says a new study validates potential of its COVID-19 therapy

BlackJack3D/E+ via Getty Images Claritas Pharmaceuticals (KALTF) has added ~13.3% in the pre-market after the company announced a recent publication of a study validating its nitric oxide-releasing compound, R-107, as a potential therapy against COVID-19. The study conducted by clinicians at Royal Brompton & Harefield NHS Foundation Trust involved 35 Patients with COVID-19 pneumonia. They were given inhaled nitric oxide as part of routine care when they failed to respond to best standard treatments, the company said, adding “this led to significant improvements in oxygen levels and improvements in ventilatory efficiency at 24 hours and for up to five days.” In June 2020, Claritas disclosed pre-clinical results indicating that R-107 rapidly converted to active payload R-100 in rats followed by a sustained release of nitric oxide in their lung tissues.

For further details see:

Claritas says a new study validates potential of its COVID-19 therapy